Lumos Diagnostics (ASX:LDX)
Company Profile
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Lumos Diagnostics.
RELATED STOCKHEAD STORIES
Lumos soars on US wins for FebriDx point-of-care respiratory test
Health Check: Drug sector panic sets in at the prospect of a Trump tariff ‘pharma-geddon’
Scott Power: ASX health stocks fall but… Orthocell nails its US FDA approval
Scott Power: ASX health sector down in week of good and bad news
Emerging ASX healthcare innovators are ready to impress at HealthInvest 2025
The Ethical Investor: Family offices, led by Aussie moguls, drive sustainability investments
Biocurious: FDA approval remains the Holy Grail for ASX life science stocks
Lumos expands development deal with Hologic for premature birth test
Health Check: More biotechs change their names, but will they smell just as sweet?
Buddying up: How small ASX healthcare stocks are teaming with giants for growth
ASX Quarterly Health Wrap: Blinklab starts key FDA study, Mach 7 set to meet FY25 guidance
Lumos teams with MedPro to expand US reach of FebriDx point-of-care respiratory test
Road to 2025: How Lumos has diagnosed its place in the market
